Cell Therapeutics (CTIC)

0.91 -0.01 -1.09% May 25, 11:00PM Go Pro

Watch this stock

Cell Therapeutics Tangible Book Value: 25.65M

View CTIC Tangible Book Value with YCharts Pro.

Access these YCharts Pro features:

Export any data you want
Save any chart as an image
Utilize advanced screener power
View 30 years of financial history
over 90 advanced calculations
Enjoy an advertising free experience

and much more...

CTIC Tangible Book Value Rankings

Overall	23rd percentile	3342 of 4385
Sector	40th percentile	300 of 504 in Healthcare
Industry	41st percentile	94 of 160 in Biotechnology

CTIC Tangible Book Value Range, Past 5 Years

Minimum	-167.15M	Dec 2007
Maximum	34.73M	Dec 2011
Average	-62.78M

About Tangible Book Value

Tangible book value is calculated by subtracting intangible assets from the company's book value.

Tangible book value excludes:
- Goodwill
- Items classified as "Intangible Assets" on the balance sheet
Learn More

You may also be interested in these CTIC related companies

Options

CTIC News

How High Can Pharmacyclics Fly?
May 23, 2:53PM Fool

CELL THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
May 14, 6:08AM

Drug Approval! Oh, Wait, We Knew That Already.
May 12, 11:08AM

CellTherapeutics (CTIC) Gets Conditional EC Marketing Authorization for Pixuvri
May 11, 9:14AM Street Insider

Healthcare Business Recap: Boston Scientific’s Good News, Cell Therapeutics Pops
May 10, 5:59PM

Cell Therapeutics (CTIC) shares resume trading 25% higher
May 10, 3:01PM Street Insider

Shares of Cell Therapeutics (CTIC) to resume trading at 3pm ET
May 10, 2:45PM Street Insider

Cell Therapeutics (CTIC) Receives EU Approval for Pixuvri as Monotherapy to Treat Relapsed/Aggressive Non-Hodgkin B-Cell Lymphomas
May 10, 2:45PM Street Insider

Cell Therapeutics' Pixuvri approved in European Union
May 10, 2:31PM

Cell Therapeutics' Pixuvri Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas
May 10, 2:31PM Benzinga

InPlay: Cell Therapeutics reports Pixuvri approved in EU as monotherapy to treat adults with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
May 10, 2:30PM

Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas
May 10, 2:30PM PR Newswire

Cell Therapeutics (CTIC) trading halted with news pending
May 10, 2:26PM Street Insider

Has InterMune Become the Perfect Stock?
May 07, 9:45AM Fool

Cell Therapeutics and Savient Pharmaceuticals Look to Benefit From Shift to "First to File" Patent System
May 04, 8:20AM Marketwire

NovaBay: Tomorrow's Staple In Antimicrobial Therapy?
May 02, 4:54PM

Is This Biotech Trying to Distract Investors?
Apr 30, 3:02PM

Be careful how you interpret call selling
Apr 30, 11:14AM

4 Biotech Stocks To Acquire Now For Gains In 2013
Apr 29, 6:41AM

China Biotech In Review: A Week Of Big Deals
Apr 29, 4:48AM

CELL THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi
Apr 27, 5:18PM

CELL THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Sec
Apr 24, 4:30PM

Great Deal. Now What?
Apr 23, 4:34PM

Cell Therapeutics Inc. Earnings: Beats Analysts’ Estimates as Loss Narrows
Apr 20, 9:18AM

Cell Therapeutics, Inc. Earnings Call scheduled for 8:30 am ET today
Apr 20, 8:30AM

Q1 2012 Cell Therapeutics, Inc. Earnings Release - Time Not Supplied
Apr 20, 7:07AM

Cell Therapeutics (CTIC) Posts Narrower Q1 Loss of 9c/Share
Apr 20, 6:44AM Street Insider

CELL THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
Apr 20, 6:13AM

Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
Apr 20, 1:30AM PR Newswire

Cell Therapeutics Q1 loss: 9 cents a share
Apr 19, 8:46PM

Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Apr 19, 8:00PM PR Newswire

Healthcare Business Recap: Human Genome, Sequenom, Dendreon Shares Surge Higher
Apr 19, 5:39PM

Cell Therapeutics Juggles Chainsaws To Distract Investors From Its Dead-End Course
Apr 19, 3:12PM

From Earlier: Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis
Apr 19, 7:49AM Benzinga

Cell Therapeutics (CTIC) to Acquire Rights on S*BIO's Pacritinib JAK2 Inhibitor
Apr 19, 6:54AM Street Insider

CTI Call scheduled for 8:30 am ET today
Apr 19, 3:52AM

A $5 Million Lottery Ticket
Apr 19, 1:32AM

Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis
Apr 19, 1:30AM PR Newswire

Cell Therapeutics buys Singapore firm drug rights in $30M deal
Apr 18, 8:20PM

Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET
Apr 18, 8:00PM PR Newswire

A $5 Million Lottery Ticket
Apr 18, 3:32PM Fool

Cell Therapeutics sees gigantic call sale
Apr 04, 3:25AM

CELL THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi
Mar 30, 5:04PM

University of Washington enrolls patients Cell Therapeutics' OPAXIO study
Mar 27, 5:43AM

University of Washington's Neuro-Oncology Program to Investigate Cell Therapeutics' Drug Candidate OPAXIO™ (Paclitaxel Poliglumex) plus Radiotherapy for Glioblastoma Multiforme, a Highly Malignant Brain Cancer
Mar 27, 1:30AM PR Newswire

Cell Therapeutics and Keryx Biopharmaceuticals Hope for Help From the TREAT Act
Mar 22, 8:20AM Marketwire

3 Biotechs You Should Have Sold Years Ago
Mar 15, 3:47PM

CELL THERAPEUTICS INC Financials
Mar 14, 1:04PM

Cell Therapeutics and Avanir Pharmaceuticals Look to Make Headway in Strengthening Biotech Industry
Mar 12, 8:20AM Marketwire

Has Spectrum Pharmaceuticals Become the Perfect Stock?
Mar 09, 9:34AM

CELL THERAPEUTICS INC Files SEC form 10-K, Annual Report
Mar 08, 4:17PM

Recent Quotes

Symbol	Price	Chg	Chg %	Market Cap
CTIC	0.91	-0.01	-1.09%	206.22M
CTHR	3.89	+0.03	+0.78%	75.66M
CTGX	12.45	+0.16	+1.30%	230.70M
CTFO	4.55	-0.09	-1.94%	114.98M
CTEL	10.58	-0.19	-1.76%	408.92M
CTCT	20.58	+0.12	+0.59%	622.13M
CTCM	9.35	-0.10	-1.06%	1.471B
CTB	15.21	-0.25	-1.62%	947.58M
CTAS	37.31	-0.41	-1.09%	4.840B
CSU	9.67	+0.12	+1.26%	272.11M

Create Watchlist from Stock Quotes